CPE抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: NIH/3T3 cell lysate, Primary antibody: P09433(CPE Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09433(CPE Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09433(CPE Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of CPE Antibodies**

CPE (Clostridium perfringens enterotoxin) antibodies target a key virulence factor produced by Clostridium perfringens, a Gram-positive bacterium responsible for food poisoning and gastrointestinal diseases. CPE is a pore-forming toxin encoded by the *cpe* gene, which disrupts intestinal epithelial cell integrity by binding to claudin receptors, leading to cell lysis, fluid loss, and inflammation.

Antibodies against CPE are primarily studied for their diagnostic and therapeutic potential. In diagnostics, they enable detection of CPE in clinical or food samples, aiding outbreak investigations. Therapeutically, neutralizing antibodies can block toxin-receptor interactions or pore formation, mitigating intestinal damage. Research has explored monoclonal antibodies (mAbs) for passive immunization, showing efficacy in preclinical models.

CPE antibodies also contribute to understanding toxin mechanisms and vaccine development. While no licensed CPE vaccine exists, studies suggest antibodies induced by toxoid or recombinant CPE vaccines protect against toxin effects. However, challenges remain, including toxin variability and optimizing antibody delivery. Overall, CPE antibodies represent a critical tool for combating C. perfringens infections, bridging diagnostics, therapy, and preventive research.